Product Images Pemetrexed

This is a chart showing the survival probability of two chemotherapy treatments, Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The survival time of patients who underwent PC and GC treatments are plotted against the months post-treatment. The chart also shows the number of patients at risk in each treatment group.*

This appears to be a survival probability graph showing the outcomes of two treatments, Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC), after a certain amount of time (measured in months). The patients at risk for each treatment are indicated at each time point.*

The text describes the survival probability for two treatments for an unknown type of cancer: Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The data provided shows the number of patients at risk and the survival time, in months, for each treatment. However, the types of cancer and the extent of the study are not available.*

This table illustrates the survival probability of patients treated with two different drugs over a period of several months. The drugs are referred to as Pemetrexed and Paccho. The table lists the number of patients at risk for each treatment at different intervals of time in months, from 0 to 15. The table does not provide any additional information about the patients or the study design.*

This is a description of a medication with NDC number 0409-1060-01 containing 100 mg of pemetrexed in each vial. It should be stored at 20 to 25 degrees Celsius, with limited excursions allowed to 15 to 0 degrees Celsius as per USP controlled room temperature requirements. The medication should be used within 24 hours after reconstitution and the dosage information should be found in the prescribing information. It is indicated for intravenous infusion after the administration of folic acid and vitamin B12 supplementation. Unused portions of the single-dose vial should be discarded. There is a warning that the medication is hazardous.*

This is a description of a prescription drug for injection called Pemetrexed. The drug comes in a single-dose vial containing 500mg of lyophilized Pemetrexed powder for intravenous infusion after dilution. There is a warning that the drug is hazardous and any unused portion should be discarded. The National Drug Code (NDC) for the drug is 0409-1061-01.*

Pemetrexed for Injection 500mg/vial is a lyophilized single-dose vial medication used for intravenous infusion after dilution. The recommended dosage must be determined by a physician. The drug contains 100 mg of mannitol and 25 mg/mL of pemetrexed. It must be reconstituted with 20 mL of 0.5% Sodium Chloride Injection, USP. The infusion solution can be diluted with 0% Sodium Chloride Injection, USP. The solution must be used within 124 hours of initial reconstitution. The drug must be stored at a controlled temperature between 10-15°C (59F-86F) for a maximum of 128 hours from the time of reconstitution. The manufacturer is Zydus HospieaOncology Pt Lid, India, and it is distributed by Hospira in Lake Forest, Illinois, USA.*

This text contains information about the drug Pemetrexed, which is a hazardous drug and is to be used for intravenous infusion after dilution. The vial contains 1 gram of Pemetrexed along with mannitol and no preservative. The recommended dosage of the drug is not mentioned, and one needs to refer to the prescribing information. The process of reconstitution and dilution is explained, and the solution should be administered within 24 hours of reconstitution. The storage conditions of the drug and the reconstituted solution are also mentioned. The drug is manufactured by Zydus Hospira Oncology in Ahmedabad, India, and distributed by Hospira Inc.*